TD Cowen analyst Charles Ryhee lowered the firm’s price target on CVS Health to $111 from $118 and keeps an Outperform rating on the shares. The analyst lowered the target to reflect the pull forward of dilution and lower near-term adjusted EPS growth. Long-term, however, we continue to like CVS health’s position in the market.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on CVS:
- ‘I don’t see a big recession’: BlackRock boss Larry Fink dismisses concerns of an economic downturn this year — here are 3 top stocks to bet on it
- Ex-Dividend Date Nearing for These 10 Stocks – Week of April 17, 2023
- Grab 2 Analyst Favorite Stocks as They Go Ex-Dividend Next Week
- 3 Consumer-Facing Stocks Boasting “Strong Buy” Ratings from Analysts
- CVS Health resumed with a Hold at Deutsche Bank
